Why AnaptysBio, Inc.’s (ANAB) Stock Is Down 5.51%
As of Wednesday, September 23, AnaptysBio, Inc.’s ANAB share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Commentary & Analysis
Why AnaptysBio, Inc.’s (ANAB) Stock Is Down 5.83%
As of Tuesday, September 22, AnaptysBio, Inc.’s ANAB share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About AnaptysBio, Inc.'s Q3 Earnings
AnaptysBio, Inc.'s fiscal Q3 earnings report was released on Monday, September 21. Let's dive in to see if (ANAB) missed or beat analyst's expectations.Michael Rose
Is AnaptysBio, Inc. (ANAB) Overvalued?
We dive into why AnaptysBio, Inc. (ANAB) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Tudor Pop
Why AnaptysBio, Inc.’s (ANAB) Stock Is Up 6.10%
As of Thursday, July 23, AnaptysBio, Inc.’s ANAB share price has surged by 6.10%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ANAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,381.5 | $239.3 | 50% |
|
| Shares Out (Mil) | 28.7 | 54.0 | 36% |
|
| Institutional Ownership | 96.9% | 93.1% | 71% |
|
| Float (Mil) | 20.4 | 41.4 | 29% |
|
| Beta | 0.41 | 0.95 | 23% |
|
| Avg Daily Volume (000s) | 645 | 613 | 62% |
|
| Price Change (52-week) |
54.7% | 49.1% | 86% |
|
| Growth | ANAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.9% | 12.5% | 62% |
|
| Net Income (5yr) | 45.6% | (10.1%) | 93% |
|
| EPS (5yr) | 39.7% | 15.8% | 88 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.5%) | (15.7%) | 40% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 4 | |
| Current EPS | $0.796 | $4.350 | $5.068 | |
| Month Ago EPS | $0.477 | ($0.231) | $5.235 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.384 | ($0.231) | $5.235 | |
| Year/Year Chg | (143.2%) | (53.8%) | (41.4%) | |
| Financials | ANAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $106 | $37 | 27% |
|
| Net Income (TTM) (Mil) | $262 | ($44) | 71% |
|
| EPS (TTM) | $9.041 | ($1.600) | 93% |
|
| Operating Cash Flow (TTM) (Mil) | ($105) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $275 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $1,585 | $175 | 46% |
|
| Valuation | ANAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 105.02 | 2.30 | 99% |
|
| P/E | 4.9 | 19.1 | 4% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 1.0 | 4% |
|
| Ratios | ANAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 105.0% | 67.3% | 100% |
|
| Net Margin | 247.0% | (74.8%) | 100% |
|
| ROA | 69.7% | (47.6%) | 100% |
|
| ROE | na | (54.9%) | na |
|
| Liabilities to Assets | 96.1% | 29.3% | 93% |
|
| F-Score | 3 | 3 | na |
|
AnaptysBio, Inc. did not pass any screens on 10/8/2026.
